SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Sick Visit — Yul Brynner

PatientYul Brynner
Date of birth1963-07-11
IdentifiersMRN HR-ML020-SYN; SSN (made up) 000-20-4572
Document date2026-10-20
AuthorSimon Achterberg, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Itchy rash on the chest, back, and arms for four days, during pembrolizumab treatment. [S]

History of Present Illness

Mr. Brynner is a 63-year-old man with stage IVB adenocarcinoma of the left upper lobe (PD-L1 70 percent, no actionable alteration) who had his second pembrolizumab infusion one week ago and his first zoledronic acid dose the same day. He asked for a same-day visit for an itchy rash. Four days ago he noticed small red bumps on his chest that have spread to his upper back and the inner arms. The itching is worst at night and in the heat of the stage lights at rehearsal, but he is sleeping. He has had no blisters, peeling, mouth or eye soreness, genital sores, or fever. The aches he had for a day after the zoledronic acid dose have gone. He has started no new soap, detergent, or medicine other than the infusions. He has had no diarrhea, abdominal pain, cough, breathlessness, headache, unusual fatigue, or yellowing of the skin or eyes. His voice remains improved since the injection two weeks ago. [S]

ElementDetail
OnsetFour days ago, three and a half weeks after the first pembrolizumab dose and three days after the second
LocationChest, upper back, and inner arms; face, palms, soles, and mucous membranes spared
DurationFour days, slowly spreading
CharacterSmall red raised spots that join in places; itchy
SeverityMild; about 8 percent of body surface area; sleeping and working
TimingItching worst at night and under hot stage lights
ContextOn pembrolizumab every 3 weeks; first zoledronic acid dose one week ago; no new exposures
Modifying factorsCool showers help; nothing taken
Associated signs and symptomsDenies fever, blisters, mucosal sores, diarrhea, cough, breathlessness, headache, and jaundice

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, chills, or unusual fatigue
IntegumentaryPositiveItchy red rash on the trunk and arms; no blisters or peeling
EyesNegativeNo redness, pain, or change in vision
Ears, nose, mouth, and throatNegativeNo mouth sores; voice improved
RespiratoryNegativeNo new cough or breathlessness
GastrointestinalNegativeNo diarrhea, abdominal pain, or dark urine
EndocrineNegativeNo headache, dizziness, heat or cold intolerance, or excessive thirst

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeksEvery 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panelIntravenous route2026-09-22activeS
Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastasesEvery 12 weeks, after calcium and creatinine, with a dental examination done firstIntravenous route2026-10-13activeS
Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acidOne tablet by mouth dailyOral route2026-10-13activeS
Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds)Apply a thin layer twice daily for up to two weeksTopical route2026-10-20activeS
Cetirizine 10 mg oral tablet, one tablet daily as needed for itchingOne tablet by mouth daily as needed for itchingOral route2026-10-20activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-20Body height178cmS
2026-10-20Body weight72kgS
2026-10-20Body mass index (BMI) [Ratio]22.7kg/m2S
2026-10-20Systolic blood pressure126mm[Hg]S
2026-10-20Diastolic blood pressure78mm[Hg]S
2026-10-20Heart rate78/minS
2026-10-20Respiratory rate16/minS
2026-10-20Body temperature36.7CelS
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-20Thyrotropin [Units/volume] in Serum or Plasma2.6m[IU]/L0.4-4 mIU/LNormalS
2026-10-20Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
2026-10-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-55 U/LNormalS
2026-10-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L8-48 U/LNormalS
2026-10-20Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-10-20Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.7-1.3 mg/dLNormalS
2026-10-20Eosinophils [#/volume] in Blood by Automated count0.6210*3/uL0-0.5 10*3/uLHighS

Physical Exam

Vital signs recorded on 2026-10-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell and comfortable; afebrile at 36.7 °C
SkinDiscrete and partly joined pink macules and papules over the anterior chest, upper back, and inner upper arms, about 8 percent of body surface area; scratch marks; no blisters, target lesions, skin pain, or peeling; Nikolsky sign negative
Mucous membranesMouth, lips, and eyes normal
Lymph nodesNo new enlargement
LungsClear; oxygen saturation 97 percent
AbdomenSoft and non-tender; no liver enlargement

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notesactiveconfirmed C34.12S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983.
Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer.
Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary windowactiveconfirmed J38.01S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor.
Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosisactiveconfirmed R91.8S — Synthetic presenting imaging finding, recorded before the tissue diagnosis.
Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco sinceactiveconfirmed Z87.891S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts.
Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement)activeconfirmed L27.0S — Synthetic common immune-related adverse event on checkpoint inhibitor therapy.

Assessment and Plan

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021)

Follow-up: Skin check at the preventive visit next week, or sooner as above. Cycle 3 in two weeks. Next scheduled visit 2026-10-27: periodic adult preventive visit. [S]